샘플 요청 목록

 카트 문의
시장보고서
상품코드
2040816

췌장암 진단 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 검사 유형별, 암 유형별, 용도별, 지역별 및 부문별 예측(2026-2033년)

Pancreatic Cancer Diagnostic Market Size, Share & Trends Analysis Report By Product, Test Type (Imaging Test, Biopsy, Blood Test), By Cancer Type (Exocrine, Endocrine), By End Use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: 구분자 Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




가격
Unprintable PDF & Excel (Single User License) help
보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.
US $ 5,950 금액 안내 화살표 ￦ 9,083,000
Printable PDF & Excel (5-User License) help
보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.
US $ 6,950 금액 안내 화살표 ￦ 10,609,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.
US $ 8,950 금액 안내 화살표 ￦ 13,663,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

췌장암 진단 시장 요약

세계의 췌장암 진단 시장 규모는 2025년에 28억 달러로 추계되며, 2033년까지 51억 5,000만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 6.83%로 성장할 것으로 전망되고 있습니다.

췌장암 발병률 증가, 조기 발견에 대한 관심 증가, 분자 진단 및 영상 진단 기술의 발전이 세계 시장의 주요 촉진요인으로 작용하고 있습니다.

또한 액체생검 및 AI 지원 영상 진단의 도입 확대와 더불어 신흥 국가의 헬스케어 인프라 및 암 검진 프로그램 확대는 시장 성장을 더욱 촉진하고 있습니다. 췌장암은 전 세계에서 암으로 인한 사망의 주요 원인 중 하나이며, 진행 단계에서의 진단과 조기 발견 수단의 한계로 인해 질병 부담은 빠른 속도로 증가하고 있습니다. 2026년 1월에 발표된 미국암협회(American Cancer Society)의 'Cancer Facts &Figures'에 따르면 5년 상대생존율은 여전히 약 13%에 불과해 이 질환의 예후가 여전히 좋지 않다는 점을 강조하고 있습니다. 2026년 미국에서만 6만 7,530명의 신규 환자 발생과 5만 2,740명이 사망할 것으로 예상되며, 췌장암은 전체 암 진단의 약 3%에 불과하지만 암 관련 사망의 세 번째 원인으로 꼽히고 있습니다.

특히 주목할 점은 1990년대 이후 발병률이 연간 약 1%의 속도로 증가하고 있다는 점입니다. 국소 진행 단계에서 진단되는 환자는 약 17%에 불과하며, 이 경우 5년 생존율은 약 44%이지만, 대부분의 경우 진행 단계에서 발견되어 생존율이 현저히 낮습니다. 이러한 추세는 조기 발견과 고급 진단 솔루션의 개선이 시급하다는 것을 강조하고 있습니다.

또한 치료 결과를 개선하기 위해서는 조기 진단이 매우 중요합니다. 그 결과, 시장 진입 기업과 의료 기관은 정기 검진 및 검진 실시를 촉진하기 위해 자금 지원 구상, 인식 제고 캠페인 및 조사 프로그램에 대한 투자를 점점 더 많이 늘리고 있습니다. 이러한 전략적 노력은 여전히 상대적으로 낮은 조기 발견율을 높이고 환자의 전반적인 생존율을 개선하는 데 초점을 맞추고 있습니다. 이러한 노력은 췌장암 진단 능력 향상을 지원하고 췌장암 진단 산업의 성장을 촉진할 것으로 기대됩니다.

예를 들어 췌장암 행동 네트워크(Pancreatic Cancer Action Network)는 지난 11월 췌장암 조기 발견을 촉진하고 치료 저항성을 극복하며 췌장암 치료 결과를 개선하기 위해 여러 기관의 과학자들을 지원하기 위한 새로운 연구 보조금 지원을 발표했습니다. 이러한 자금 지원 구상은 특히 중요한 연구 격차를 해소하고 진단 및 치료 접근 방식의 혁신을 가속화하는 것을 목표로 합니다.

췌장 악성종양 환자 수가 크게 증가함에 따라 선별검사 도입이 촉진되고 있으며, 새로운 진단 솔루션에 대한 강력한 수요가 발생하고 있습니다. 현재 질병을 발견하기 위해 바이오마커 검사, 간기능 검사, 생검, 첨단 영상 진단 기술 등의 진단법이 널리 사용되고 있습니다. 또한 첨단 진단 솔루션에 대한 수요가 증가함에 따라 각 제조사들은 혁신적이고 정밀한 검사 기술을 개발하고 있습니다. 예를 들어 2026년 3월 미국 국립보건원(NIH)의 지원을 받은 연구진은 여러 단백질 바이오마커를 결합한 새로운 혈액 검사를 개발했습니다. 이 검사는 조기 췌장암을 포함한 췌장암을 90% 이상의 정확도를 보여줌으로써 비침습적 조기 발견 솔루션을 향한 큰 진전을 이루었습니다.

또한 악성 종양 검진 프로그램의 증가는 췌장암 진단 제품에 대한 글로벌 수요를 견인하고 있습니다. 세계보건기구(WHO), 미국 질병예방통제센터(CDC), 췌장암 액션 네트워크(Pancreatic Cancer Action Network) 등의 조직 간 협력은 인식 개선과 진단의 진전을 통해 시장 성장을 지원할 것으로 기대됩니다. 또한 췌장 악성 종양의 조기 스크리닝, 위험 평가 및 바이오마커 기반 탐지를 촉진하기 위한 여러 노력이 진행되고 있습니다.

예를 들어 2025년 10월 췌장암 행동 네트워크는 초기 증상, 위험 요인 및 적시 진단의 중요성에 대한 인식을 높이기 위해 'Shine a Light' 캠페인을 시작했습니다. 또한 세계췌장암연합이 세계 췌장암 인식개선 활동 10주년을 기념해 개최한 '2025 세계 췌장암의 날'과 같은 세계적인 노력으로 증상, 유전자 검사, 진단 경로에 대한 인식이 크게 높아졌고, 그 결과 전 세계에서 췌장암 진단 기술 도입이 가속화되고 있습니다.

분자진단의 발전은 췌장암 진단 산업에 큰 성장 기회를 제공하고 있습니다. 분자 진단 검사를 통해 췌장 악성 종양과 관련된 특정 유전자 변이 및 바이오마커를 식별할 수 있으며, 조기 진단 및 보다 표적화된 치료 접근을 촉진할 수 있습니다. 예를 들어 순환 종양 DNA(ctDNA)를 검출하는 액체생검 기반 검사는 췌장암의 조기 발견을 돕기 위해 점점 더 많은 개발 및 검증이 진행되고 있습니다.

또한 영상 진단, 병리진단, 바이오마커 기반 검사에 인공지능(AI)을 통합함으로써 조기 진단의 정확성과 효율성을 높일 수 있을 것으로 기대됩니다. 2024년 9월 주요 소화기병 및 종양학 학술지에 게재된 최근 연구는 AI를 활용한 내시경 초음파 검사 및 바이오마커 분석이 기존 진단법 대비 췌장 조기 병변의 검출 민감도를 향상시켜 첨단 진단 기술의 보급을 촉진하고 있다고 강조했습니다. 보급이 촉진되고 있습니다.

자주 묻는 질문

  • 췌장암 진단 시장 규모는 어떻게 예측되나요?
  • 췌장암 진단 시장의 주요 촉진 요인은 무엇인가요?
  • 췌장암의 5년 상대 생존율은 얼마인가요?
  • 췌장암 조기 발견을 위한 최근의 노력은 무엇인가요?
  • 췌장암 진단을 위한 현재의 진단법은 무엇이 있나요?
  • AI 기술이 췌장암 진단에 미치는 영향은 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 개요

제3장 췌장암 진단 시장 : 변수, 동향, 범위

제4장 췌장암 진단 시장 부문 분석 : 제품별, 2021-2033년

제5장 췌장암 진단 시장 부문 분석 : 테스트 유형별, 2021-2033년

제6장 췌장암 진단 시장 부문 분석 : 암 유형별, 2021-2033년

제7장 췌장암 진단 시장 부문 분석 : 최종 사용별, 2021-2033년

제8장 췌장암 진단 시장 : 지역별 추정·동향 분석

제9장 경쟁 구도

KSA 26.06.02

Pancreatic Cancer Diagnostic Market Summary

The global pancreatic cancer diagnostic market size was estimated at USD 2.80 billion in 2025 and is projected to reach USD 5.15 billion by 2033, growing at a CAGR of 6.83% from 2026 to 2033. The increasing prevalence of pancreatic cancer, the growing emphasis on early detection, and advancements in molecular diagnostics and imaging technologies are the key drivers of the global market.

In addition, the rising adoption of liquid biopsy and AI-assisted imaging, coupled with expanding healthcare infrastructure and oncology screening programs in emerging economies, is further supporting market growth. Pancreatic cancer is one of the leading causes of cancer-related death across the globe, and the burden of disease is escalating at a significant pace, driven by late-stage diagnosis and limited early detection options. According to the American Cancer Society's Cancer Facts & Figures, published in January 2026, the five-year relative survival rate remains approximately 13%, underscoring the persistently poor prognosis of the disease. In 2026 alone, an estimated 67,530 new cases and 52,740 deaths are projected in the United States, making pancreatic cancer the third leading cause of cancer-related mortality despite accounting for only about 3% of all cancer diagnoses.

Notably, incidence has been increasing by nearly 1% annually since the 1990s. Only about 17% of patients are diagnosed at a localized stage, where the five-year survival rate is about 44%, whereas most cases are detected at advanced stages, with significantly lower survival. These trends highlight the urgent need for improved early detection and advanced diagnostic solutions.

Moreover, early disease diagnosis is critical to improving treatment outcomes. Consequently, market participants and healthcare organizations are increasingly investing in funding initiatives, awareness campaigns, and research programs to encourage routine checkups and screening practices. These strategic efforts are focused on enhancing early-stage detection rates, which remain comparatively low, and improving overall patient survival. Such initiatives are expected to support the advancement of diagnostic capabilities and drive growth in the pancreatic cancer diagnostics industry.

For instance, in November 2025, the Pancreatic Cancer Action Network announced new research grant investments to support scientists across multiple institutions in advancing early detection, addressing therapeutic resistance, and improving treatment outcomes for pancreatic cancer. These funding initiatives are specifically designed to bridge critical research gaps and accelerate innovation in diagnostic and therapeutic approaches.

The significant rise in the number of pancreatic malignancy cases is driving the adoption of screening tests and generating strong demand for novel diagnostic solutions. Currently, diagnostic modalities such as biomarker assays, liver function tests, biopsies, and advanced imaging technologies are widely utilized for disease detection. Moreover, the growing demand for advanced diagnostic solutions is prompting manufacturers to develop innovative, high-precision testing technologies. For instance, in March 2026, researchers supported by the National Institutes of Health developed a novel blood-based test combining multiple protein biomarkers that demonstrated over 90% accuracy in detecting pancreatic cancer, including early-stage cases, highlighting significant progress toward non-invasive early-detection solutions.

Moreover, the growing number of programs promoting screening for malignant tumors is driving worldwide demand for pancreatic cancer diagnostic products. Partnerships among organizations such as the World Health Organization, Centers for Disease Control and Prevention, and the Pancreatic Cancer Action Network are expected to support market growth by advancing awareness and diagnosis. In addition, multiple initiatives are encouraging early screening, risk assessment, and biomarker-based detection of pancreatic malignancies.

For instance, in October 2025, Pancreatic Cancer Action Network launched its Shine a Light campaign to raise awareness of early symptoms, risk factors, and the importance of timely diagnosis. Furthermore, global initiatives such as World Pancreatic Cancer Day 2025, which the World Pancreatic Cancer Coalition celebrated to mark 10 years of driving global awareness, have significantly increased awareness of symptoms, genetic testing, and diagnostic pathways, thereby accelerating the adoption of pancreatic cancer diagnostic technologies worldwide.

Advancements in molecular diagnostics are creating significant growth opportunities in the pancreatic cancer diagnostics industry. Molecular diagnostic tests enable the identification of specific genetic mutations and biomarkers associated with pancreatic malignancies, facilitating earlier diagnosis and more targeted treatment approaches. For example, liquid biopsy-based tests that detect circulating tumor DNA (ctDNA) are increasingly being developed and validated to support early-stage detection of pancreatic cancer.

Moreover, the integration of artificial intelligence (AI) in imaging, pathology, and biomarker-based testing is expected to enhance early diagnostic accuracy and efficiency. Recent studies published in September 2024 in leading gastroenterology and oncology journals highlight that AI-assisted endoscopic ultrasound and biomarker analysis demonstrate improved sensitivity in detecting early pancreatic lesions compared to conventional diagnostic methods, thereby supporting increased adoption of advanced diagnostic technologies.

Global Pancreatic Cancer Diagnostic Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global pancreatic cancer diagnostic market report based on the product, test type, cancer type, end use, and regions.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Consumables
  • Services
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging Test
    • CT Scan
    • MRI
    • Ultrasound
    • PET
    • Others
  • Biopsy
  • Blood Test
    • Liver Function Tests
    • Tumor Markers
    • Others
  • Others
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Exocrine
    • Adenocarcinoma
    • Squamous Cell Carcinoma
    • Adenosquamous Carcinoma
    • Colloid Carcinoma
  • Endocrine
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Clinics
  • Laboratories
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Device type
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Type Outlook Test
    • 2.2.3. Cancer Type Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pancreatic Cancer Diagnostic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of pancreatic cancer
      • 3.2.1.2. Growing emphasis on early detection
      • 3.2.1.3. Advancements in molecular diagnostics
      • 3.2.1.4. Rising adoption of liquid biopsy and AI-assisted imaging
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory and compliance challenges
      • 3.2.2.2. Sample collection errors and user compliance
  • 3.3. At-home Blood Collection Kits/Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Pancreatic Cancer Diagnostic Market Segment Analysis, By Product, 2021 - 2033 (USD Million)

  • 4.1. Definition and Scope
  • 4.2. Product Market Share Analysis, 2025 & 2033
  • 4.3. Segment Dashboard
  • 4.4. Global Pancreatic Cancer Diagnostic Market, by Product, 2021 to 2033
  • 4.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 4.5.1. Instruments
      • 4.5.1.1. Instruments market estimates and forecast, 2021 - 2033 (USD Million)
    • 4.5.2. Consumables
      • 4.5.2.1. Consumables market estimates and forecast, 2021 - 2033 (USD Million)
    • 4.5.3. Services
      • 4.5.3.1. Services market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 5. Pancreatic Cancer Diagnostic Market Segment Analysis, By Test Type 2021 - 2033 (USD Million)

  • 5.1. Definition and Scope
  • 5.2. Test Type Market Share Analysis, 2025 & 2033
  • 5.3. Segment Dashboard
  • 5.4. Global Pancreatic Cancer Diagnostic Market, by Test Type, 2021 to 2033
  • 5.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 5.5.1. Imaging Test
      • 5.5.1.1. Imaging test market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.1.2. CT Scan
        • 5.5.1.2.1. CT scan market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.1.3. MRI
        • 5.5.1.3.1. MRI market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.1.4. Ultrasound
        • 5.5.1.4.1. Ultrasound market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.1.5. PET
        • 5.5.1.5.1. PET market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.1.6. Others
        • 5.5.1.6.1. Others market estimates and forecast, 2021 - 2033, (USD Million)
    • 5.5.2. Biopsy
      • 5.5.2.1. Biopsy market estimates and forecast, 2021 - 2033, (USD Million)
    • 5.5.3. Blood Test
      • 5.5.3.1. Blood test estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.3.2. Liver Function Tests
        • 5.5.3.2.1. Liver function tests market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.3.3. Tumor Markers
        • 5.5.3.3.1. Tumor markers market estimates and forecast, 2021 - 2033, (USD Million)
      • 5.5.3.4. Others
        • 5.5.3.4.1. Others market estimates and forecast, 2021 - 2033, (USD Million)
    • 5.5.4. Others
      • 5.5.4.1. market estimates and forecast, 2021 - 2033, (USD Million)

Chapter 6. Pancreatic Cancer Diagnostic Market Segment Analysis, By Cancer Type, 2021 - 2033 (USD Million)

  • 6.1. Definition and Scope
  • 6.2. Cancer Type Market Share Analysis, 2025 & 2033
  • 6.3. Segment Dashboard
  • 6.4. Global Pancreatic Cancer Diagnostic Market, by Cancer Type, 2021 to 2033
  • 6.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 6.5.1. Exocrine
    • 6.5.2. Exocrine market estimates and forecast, 2021 - 2033 (USD Million)
      • 6.5.2.1. Adenocarcinoma
        • 6.5.2.1.1. Adenocarcinoma market estimates and forecast, 2021 - 2033, (USD Million)
      • 6.5.2.2. Squamous Cell Carcinoma
        • 6.5.2.2.1. Squamous cell carcinoma market estimates and forecast, 2021 - 2033, (USD Million)
      • 6.5.2.3. Adenosquamous Carcinoma
        • 6.5.2.3.1. Adenosquamous carcinoma market estimates and forecast, 2021 - 2033, (USD Million)
      • 6.5.2.4. Colloid Carcinoma
        • 6.5.2.4.1. PET market estimates and forecast, 2021 - 2033, (USD Million)
    • 6.5.3. Endocrine
      • 6.5.3.1. Endocrine market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. Pancreatic Cancer Diagnostic Market Segment Analysis, By End Use, 2021 - 2033 (USD Million)

  • 7.1. Definition and Scope
  • 7.2. End Use Market Share Analysis, 2025 & 2033
  • 7.3. Segment Dashboard
  • 7.4. Global Pancreatic Cancer Diagnostic Market, By End Use, 2021 to 2033
  • 7.5. Market Size & Forecasts and Trend Analyses, 2021 to 2033
    • 7.5.1. Hospitals
      • 7.5.1.1. Hospitals market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.2. Clinics
      • 7.5.2.1. Clinics market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.3. Laboratories
      • 7.5.3.1. Laboratories market estimates and forecast, 2021 - 2033 (USD Million)
    • 7.5.4. Others
      • 7.5.4.1. Others market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. Pancreatic Cancer Diagnostic Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2025
    • 9.3.4. Thermo Fisher Scientific, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. QIAGEN
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Illumina, Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. F. Hoffmann-La Roche Ltd.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. BD
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Agilent Technologies, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Myrlad Genetics, Inc.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Koninklijke Philips N.V.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Abbott
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Danaher
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Hitachi Ltd
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Prestige Biopharma Ltd.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. BioMarket Startegies
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives
    • 9.3.17. ASURAGEN, INC.
      • 9.3.17.1. Company overview
      • 9.3.17.2. Financial performance
      • 9.3.17.3. Product benchmarking
      • 9.3.17.4. Strategic initiatives
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기